(MENAFN- Straits Research)
Market Overview
The North America pharmacogenomics market size was valued at USD 3.92 billion in 2025 and is projected to grow from USD 4.41 billion in 2026 to reach USD 11.41 billion by 2034, growing at a CAGR of 12.6% during the forecast period 2026–2034.
In pharmacogenomics, genes are studied concerning drug response. This field combines pharmacology (the science of pharmaceuticals) and genomics (the study of genes and their functions) to create effective, safe treatments depending on a person's genetic composition.
Many medications on the market today are "one size fits all", but they don't work the same for everyone. It's difficult to tell who will benefit from a drug and who will have side effects (called adverse drug reactions). Adverse medication reactions cause a considerable number of hospitalisations and deaths.
Researchers are trying to figure out how genetic variations affect the body's response to drugs. These genetic distinctions will be utilized to forecast whether a treatment will be successful for a specific person and which dosage will help avoid unpleasant drug reactions. Conditions like clopidogrel resistance, warfarin sensitivity, warfarin resistance, malignant hyperthermia, Stevens-Johnson syndrome/toxic epidermal necrolysis, and thiopurine S-methyltransferase deficiency can change how a person responds to certain medicines.
The science of pharmacogenomics is expanding, and clinical studies are testing new approaches. Pharmacogenomics will be utilized in the future to develop personalized medications to treat a variety of diseases, including cardiovascular disease, Alzheimer's disease, cancer, and asthma.
Download a Free Sample To learn more about this report,
Market Dynamics
Drivers
The Incessant Need for Treatments of Debilitating Diseases Such as Cancer is the Primary Force behind the Expansion of the Market
The increased prevalence of diseases like cancer, which have no apparent cure or treatment plan advised by medical research, is driving the market. As a result, in the last decade, genomics and precision medicine have become increasingly important in the treatment of cancer patients.
In contrast to other illnesses, cancer therapy must consider both acquired (somatic) and inherited (germline) variation, which affects a drug's efficacy and safety. As a result, PGx tests have been widely used to identify treatment options.
Growing Concerns about Adverse Drug Reactions (adrs) Have Boosted the Market Significantly
In today's healthcare system, adverse pharmaceutical responses are a problem for doctors worldwide. One patient may experience adverse side effects while another does not. As a result, a community's diversity creates unanticipated reactions, impeding the existing healthcare market scenario. Many pharmaceuticals have life-threatening side effects in patients. According to FDA data from 2018-2019, 6.7% of hospitalized patients experienced an adverse medication reaction, with a 0.32 per cent death rate. According to these estimates, there are around 2,216,000 severe ADRs in hospitalized patients each year, resulting in over 106,000 deaths.
North America Pharmacogenomics market solutions are a unique solution to the issue. Understanding the underlying biological mechanisms and exploiting genetic contributions for customized therapy is the core goal of pharmacogenomics.
Restraints
These Are Some of the Issues Hindering the Market Growth of Pharmacogenomics
Infrastructure is one of the significant roadblocks to clinical pharmacogenomics. The ethical and political frameworks, the re-education of many different groups in the health sector, and the physical infrastructure for pharmacogenomic tests are all part of this. These obstacles are not exclusive to pharmacogenomic tests. After the general infrastructure has been put up for a single pharmacogenomic test, subsequent tests will only necessitate minimal infrastructure changes. Making a case for the initial investment is the issue.
A lack of healthcare professional education hampers the widespread use of pharmacogenomics. A perceived shortage of pharmacogenomic education is hampering Pharmacogenomics' market expansion among various health care practitioners.
Many people have expressed concerns regarding the ethical implications of using genetic data in medicine. This is perhaps more important in the context of pharmacogenomics for genetic testing that predicts efficacy rather than adverse outcomes. The three primary categories of ethical dilemmas are the equitable provision of healthcare, the possibility that genetic polymorphisms may track with race or ethnicity, and the considerations of consent, access, and privacy surrounding pharmacogenomic information.
North America Pharmacogenomics Market Segmental Analysis
By Technology
The North America pharmacogenomics market is segmented into microarray, sequencing, polymerase chain reaction, and others based on technology. Microarray technology is used to analyze multiple genetic variations simultaneously and supports the identification of genetic markers associated with drug response. Sequencing technologies provide detailed information about genetic variations and are increasingly applied in personalized medicine and pharmacogenomic research. Polymerase chain reaction is widely used for targeted amplification and detection of specific genetic variants, making it useful for clinical and research applications. The others segment includes additional technologies used for genetic analysis and pharmacogenomic testing.
Request Customization to receive a tailored report.
By Application
The North America pharmacogenomics market is segmented into oncology, cardiovascular diseases, neurological diseases, and others based on application. Oncology applications use pharmacogenomic information to understand how genetic variations influence responses to cancer therapies and support more personalized treatment strategies. Cardiovascular applications focus on identifying genetic factors that can affect responses to medications used to manage cardiovascular conditions. Neurological applications utilize pharmacogenomic testing to help understand variations in drug response associated with neurological and psychiatric treatments. The others segment includes additional therapeutic areas where genetic information can support drug selection, dosage decisions, treatment optimization, and the development of personalized healthcare approaches.
Speak to an Analyst to discuss market opportunities.
North America Pharmacogenomics Market Regional Outlook
North America Pharmacogenomics Market Analysis
North America is the leading market for pharmacogenomics, supported by advanced healthcare infrastructure, strong genomic research capabilities, increasing adoption of precision medicine, and growing awareness of personalized treatment. The region benefits from the expanding use of genetic testing for medication selection and dosage optimization, particularly across oncology, cardiology, neurology, and pain management. Government and private-sector initiatives supporting pharmacogenomic research and clinical implementation are also contributing to regional market development.
United States Pharmacogenomics Market Insights
The United States represents the largest market in North America, supported by strong genomic research capabilities, widespread availability of genetic testing, and increasing integration of pharmacogenomic information into clinical decision-making. Growing adoption of personalized medicine and precision oncology, along with investments in genomic technologies and clinical research, continues to support market development.
Canada Pharmacogenomics Market Insights
Canada is an important market for pharmacogenomics, supported by increasing investment in genomic medicine, precision healthcare initiatives, and clinical research. Growing awareness of genetic testing for optimizing medication selection and dosing is encouraging adoption across healthcare settings. The expansion of genomic technologies and personalized healthcare approaches is expected to further support market growth.
List of Key and Emerging Players in North America Pharmacogenomics Market
Admera Health
Abbott Laboratories
Agilent Technologies
Novartis AG
Dynamic DNA Laboratories
Empire Genomics, LLC.
Hoffmann-La Roche Ltd.
Illumina, Inc.
OneOme, LLC
Myriad Genetics Inc.
OPKO Health, Inc. (GeneDx.)
Thermo Fisher Scientific, Inc.
AltheaDx
Key Industry Developments
May 2025: Helix expanded its pharmacogenomics portfolio with the launch of new PGx tests, including the PGx Fluoropyrimidines DPYD Test and an APOE pharmacogenomic test to support personalized treatment decisions for oncology and Alzheimer's disease patients across the United States.
November 2025: Helix partnered with University Health Network's Princess Margaret Cancer Centre in Canada to implement large-scale genomic testing for up to 100,000 patients, strengthening precision medicine infrastructure and supporting broader pharmacogenomic applications in clinical care.
February 2026: Merck and Mayo Clinic entered into a strategic research and development collaboration to integrate AI, genomic data, and advanced analytics for precision medicine and drug discovery, supporting the advancement of pharmacogenomics-driven therapeutic development in North America.
May 2026: Foundation Medicine expanded its partnership with Fulgent Genetics to launch FoundationOne® PGx, a pharmacogenetic testing solution in the United States designed to identify clinically actionable gene-drug interactions and guide personalized cancer therapy selection and dosing.
Report Scope
Comments
No comment